Roghanian, A, Teige, I, Mårtensson, L, Cox, KL, Kovacek, M, Ljungars, A, Mattson, J, Sundberg, A, Vaughan, AT, Shah, V, Smyth, NR, Sheth, B, Chan, HTC, Li, Z-C, Williams, EL, Manfredi, G, Oldham, RJ, Mockridge, CI, James, SA, Dahal, LN, Hussain, K, Nilsson, B, Verbeek, JS, Juliusson, G, Hansson, M, Jerkeman, M, Johnson, PWM, Davies, A, Beers, SA, Glennie, MJ, Frendéus, B & Cragg, MS, 2015, ‘Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo’. Cancer Cell, vol 27., pp. 473-88 Liu, B, Dhanda, A, Hirani, S, Williams, EL, Sen, HN, Estrada, FM, Ling, D, Thompson, I, Casady, M, Li, Z, Si, H, Tucker, W, Wei, L, Jawad, S, Sura, A, Dailey, J, Hannes, S, Chen, P, Chien, JL, Gordon, S, Lee, RWJ & Nussenblatt, RB, 2015, ‘CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses’. Journal of immunology (Baltimore, Md. : 1950), vol 194., pp. 5150-60 Schewitz-Bowers, LP, Lait, PJP, Copland, DA, Chen, P, Wu, W, Dhanda, AD, Vistica, BP, Williams, EL, Liu, B, Jawad, S, Li, Z, Tucker, W, Hirani, S, Wakabayashi, Y, Zhu, J, Sen, N, Conway-Campbell, BL, Gery, I, Dick, AD, Wei, L, Nussenblatt, RB & Lee, RWJ, 2015, ‘Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A’. Proceedings of the National Academy of Sciences of the United States of America. Vaughan, AT, Iriyama, C, Beers, SA, Chan, CHT, Lim, SH, Williams, EL, Shah, V, Roghanian, A, Frendéus, B, Glennie, MJ & Cragg, MS, 2014, ‘Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity’. Blood, vol 123., pp. 669-77 White, AL, Dou, L, Chan, HTC, Field, VL, Mockridge, CI, Moss, K, Williams, EL, Booth, SG, French, RR, Potter, EA, Butts, C, Al-Shamkhani, A, Cragg, MS, Verbeek, JS, Johnson, PWM, Glennie, MJ & Beers, SA, 2014, ‘Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization’. Journal of immunology (Baltimore, Md. : 1950), vol 193., pp. 1828-35 Williams, EL, Tutt, AL, Beers, SA, French, RR, Chan, CHT, Cox, KL, Roghanian, A, Penfold, CA, Butts, CL, Boross, P, Verbeek, JS, Cragg, MS & Glennie, MJ, 2013, ‘Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization’. Journal of immunology (Baltimore, Md. : 1950), vol 191., pp. 4130-40 Williams, EL, Dunn, SN, James, S, Johnson, PW, Cragg, MS, Glennie, MJ & Gray, JC, 2013, ‘Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model’. Clinical Cancer Research, vol 19., pp. 3545-55 Williams, EL, Tutt, AL, French, RR, Chan, HTC, Lau, B, Penfold, CA, Mockridge, CI, Roghanian, A, Cox, KL, Verbeek, JS, Glennie, MJ & Cragg, MS, 2012, ‘Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B)’. European Journal of Immunology, vol 42., pp. 2109-20 Lim, SH, Vaughan, AT, Ashton-Key, M, Williams, EL, Dixon, SV, Chan, HTC, Beers, SA, French, RR, Cox, KL, Davies, AJ, Potter, KN, Mockridge, CI, Oscier, DG, Johnson, PWM, Cragg, MS & Glennie, MJ, 2011, ‘Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy’. Blood, vol 118., pp. 2530-40